
JH-RE-06
CAS No. 1361227-90-8
JH-RE-06( —— )
Catalog No. M22367 CAS No. 1361227-90-8
JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 417 | Get Quote |
![]() ![]() |
10MG | 610 | Get Quote |
![]() ![]() |
25MG | 963 | Get Quote |
![]() ![]() |
50MG | 1287 | Get Quote |
![]() ![]() |
100MG | 1737 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameJH-RE-06
-
NoteResearch use only, not for human use.
-
Brief DescriptionJH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy.
-
DescriptionJH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy. JH-RE-06 unexpectedly causes dimerization of the REV1 CTD at its REV7-binding surface. It also blocks the REV1-REV7 interaction. In mice, co-administration of JH-RE-06 with cisplatin inhibits the growth of xenograft human melanomas. JH-RE-06 suppresses mutagenic TLS and increases cisplatin-induced toxicity in cultured human and mouse cell lines.
-
In VitroJH-RE-06 unexpectedly induces dimerization of the REV1 CTD at its REV7-binding surface and blocks the REV1-REV7 interaction.
-
In VivoJH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines. Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetDNA/RNA Synthesis
-
RecptorREV1-REV7
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1361227-90-8
-
Formula Weight468.72
-
Molecular FormulaC20H16Cl3N3O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:5 mg/mL (10.67 mM; Need ultrasonic)
-
SMILESO=C1C(C(CC(C)C)=O)=C(NC2=CC=C(Cl)C=C2Cl)NC3=C1C([N+]([O-])=O)=CC=C3Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wojtaszek JL, et al. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019 Jun 27;178(1):152-159.e11.
molnova catalog



related products
-
Puromycin dihydrochl...
Puromycin 2hydrochloride is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.
-
2-O-(2-Methoxyethyl)...
2'-O-(2-Methoxyethyl)adenosine is a nucleoside analog used to improve RNA target affinity and nuclease resistance of therapeutic oligonucleotides in preclin.
-
10-Formyl-5,8-dideaz...
10-Formyl-5,8-dideazafolic acid (CB3717) is a water-soluble analog of folic acid, also known as folate.